Latest Safety News

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

FBR Limited has successfully placed the shortfall from its recent Share Purchase Plan, raising an additional $288,910 through issuing over 64 million shares. This capital injection supports the company’s ongoing development of its innovative robotic technologies.

Caravel Minerals has released its first comprehensive Sustainability Report for fiscal 2025, detailing ambitious ESG initiatives and a clear roadmap toward net-zero emissions for its Caravel Copper Project in Western Australia.

Yancoal Australia Ltd reported a sharp 61% drop in net profit for the first half of 2025 amid falling coal prices and supply chain disruptions, despite a 15% rise in production. The company declared a fully franked interim dividend and is advancing strategic acquisitions and sustainability initiatives.

Liontown Resources reported a solid FY25 with A$298 million in revenue and positive EBITDA, setting the stage for a strategic underground transition in FY26 backed by a strengthened balance sheet and sustainability commitments.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.

Zimi Limited has completed its manufacturing transition, fulfilling over $1 million in backorders and restoring product availability in the Australian smart home market.

Savannah Goldfields has secured crucial environmental approvals to restart gold production at its Georgetown Gold Project, with mining at Big Reef set to begin in October 2025. The company also received approval for a tailings storage facility expansion to support future processing.

KGL Resources updates on its Jervois Copper Project optimisations and financing progress, welcoming Resource Capital Fund as a new significant shareholder. The company is capitalising on higher metal prices and exploring critical mineral opportunities.

Race Oncology has secured Investigational New Drug approval from South Korea’s regulatory authority, enabling Phase 1 clinical trials of RC220 in combination with doxorubicin for solid tumour patients across four Korean sites.

QPM Energy has reported its first-ever profit alongside a 12.6% revenue increase and significant growth in gas reserves and electricity generation capacity.

Bio-Gene Technology’s novel acaricide Flavocide demonstrated over 90% mortality against Lyme disease-carrying ticks in lab tests presented by Purdue University, highlighting its potential in public health applications.